LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153-421): Design, synthesis and biochemical evaluation

European Journal of Medicinal Chemistry

Volumn 92, Issue , 2015, Pages 890-907

  Alghamdi, Rasha H ^a   O'Reilly, Paul ^a   Lu, Chunyu ^a   Gomes, James ^a   Lagace, Thomas A ^b   Basak, Ajoy ^a,c  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

(PCSK9); Cholesterol lowering agents; Epidermal Growth Factor A (EGF A); Fluorescence quenching; Low Density Lipoprotein receptor (LDL R); PCSK9 inhibitors; Proprotein Convertase Subtilisin Kexin 9

Indexed keywords

AMINO ACID; KEXIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9; SERINE PROTEINASE; SUBTILISIN; UNCLASSIFIED DRUG; PCSK9 PROTEIN, HUMAN; PEPTIDE;

ARTICLE; BINDING AFFINITY; BIOCHEMICAL COMPOSITION; CATALYSIS; FLUORESCENCE SPECTROSCOPY; GAIN OF FUNCTION MUTATION; GEL ELECTROPHORESIS; HUMAN; HUMAN CELL; LIVER CELL; MASS SPECTROMETRY; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; SEQUENCE ANALYSIS; BIOCATALYSIS; BLOOD; CHEMISTRY; DRUG DESIGN; ENZYME ACTIVE SITE; HEPG2 CELL LINE; METABOLISM; SYNTHESIS; TUMOR CELL CULTURE;

BIOCATALYSIS; CATALYTIC DOMAIN; DRUG DESIGN; HEP G2 CELLS; HUMANS; PEPTIDES; PROPROTEIN CONVERTASES; RECEPTORS, LDL; SERINE ENDOPEPTIDASES; TUMOR CELLS, CULTURED;

EID: 84952719137     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: None     Document Type: Article

References (92)

1. N.G. Seidah, S. Benjannet, L. Wickham, J. Marcinkiewicz, S.B. Jasmin, S. Stefani, A. Basak, A. Pratt, M. Chretien, The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation, Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 928-933.
2. M. Mbikay, N.G. Seidah (Eds.), Proprotein Convertases, Springer Protocols, Humana Press, 2011, p. 367.
3. N.G. Seidah, M.S. Sadr, M. Chretien, M. Mbikay, The multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functions, J. Biol. Chem. 288 (30) (2013) 21473-21481.
4. N.G. Seidah, A. Prat, The biology and therapeutic targeting of the proprotein convertases, Nat. Rev. Drug Discov. 11 (5) (2012) 367-383.
5. A.W. Artenstein, S.M. Opal, Proprotein convertases in health and disease, N. Engl. J. Med. 365 (26) (2011) 2507-2518.
6. H. Turpeinen, Z. Ortutay, M. Pesu, Genetics of the first seven proprotein convertase enzymes in health and disease, Curr. Genomics 14 (7) (2013) 453-467.
7. F. Couture, F. D'Anjou, R. Day, On the cutting edge of proprotein convertase pharmacology: from molecular concepts to clinical applications, Biomol. Concepts 2 (5) (2011) 421-438.
8. D.F. Steiner, On the discovery of precursor processing, Methods Mol. Biol. 768 (2011) 773-811.
9. S. Kourimate, M. Chetiveaux, A.L. Jarnoux, F. Lalanne, P. Costet, Cellular and secreted pro-protein convertase subtilisin/kexin type 9 catalytic activity in hepatocytes, Atherosclerosis 206 (1) (2009) 134-140.
10. J.D. Horton, J.C. Cohen, H.H. Hobbs, Molecular biology of PCSK9: its role in LDL metabolism, Trends Biochem. Sci. 32 (2) (2007) 71-77.
11. M.C. McNutt, T.A. Lagace, J.D. Horton, Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells, J. Biol. Chem. 282 (2007) 20799-20803.
12. J. Li, C. Tumanut, J.-A. Gavigan, W.-J. Huang, E.N. Hampton, R. Tumanut, K.F. Suen, J.W.S. Trauger, G. praggon, S.A. Lesley, G. Liau, D. Yowe, J.L. Harris, Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity, Biochem. J. 406 (2007) 203-207.
13. D. Fan, P.G. Yancey, S. Qiu, L. Ding, E.J. Weeber, M.F. Linton, F. Fazio, Self-association of human PCSK9 correlates with its LDLR-degrading activity, Biochemistry 47 (6) (2008) 631-639.
14. H.J. Kwon, T.A. Lagace, M.C. McNutt, J.D. Horton, J. Deisenhofer, Molecular basis for LDL receptor recognition by PCSK9, Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 1820-1825.
15. N.G. Seidah, PCSK9 as a therapeutic target of dyslipidemia, Expert Opin. Ther. Targets 13 (1) (2009) 19-28.
16. M.A. Ausin, C.M. Hutter, R.L. Zimmern, S.E. Humphries, Familial hypercholesterolemia and coronary heart disease: a HuGE association review, Am. J. Epidemiol. 160 (5) (2004) 421-429.
17. F. Civeira, International Panel on Management of Familial Hypercholesterolemia. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia, Atherosclerosis. 173 (1) (2004) 55-68.
18. S.W. Park, Y.A. Moon, J.D. Horton, Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9 in mouse liver, J. Biol. Chem. 279 (2004) 50630-50638.
19. N. Nassoury, D.A. Blasiole, A. Tebon Oler, S. Benjannet, J. Hamelin, V. Poupon, P.S. McPherson, A.D. Attie, A. Prat, N.G. Seidah, The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR, Traffic 8 (6) (2007) 718-732.
20. M. Abifadel, M. Varret, J.P. Rabes, D. Allard, K. Ouguerram, M. Devillers, C. Cruaud, S. Benjannet, L. Wickham, D. Erlich, A. Derre, L. Villeger, M. Farnier, I. Beucler, E. Bruckert, J. Chambaz, B. Chanu, J.M. Lecerf, G. Luc, P. Moulin, J. Weissenbach, A. Prat, M. Krempf, C. Junien, N.G. Seidah, C. Boileau, Mutations in PCSK9 cause autosomal dominant hypercholesterolemia, Nat. Genet. 34 (2) (2003) 154-156.
21. M. Abifadel, L. Bernier, G. Dubuc, et al., A PCSK9 variant and familial combined hyperlipidemia, J. Med. Genet. 45 (12) (2008) 780-786.
22. M. Abifadel, J.P. Rabes, M. Devillers, A. Munnich, D. Ehrlich, C. Junien, M. Varett, C. Boileau, Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease, Hum. Mutat. 30 (2009) 520-529.
23. S. Benjannet, J. Hamelin, M. Chretien, N.G. Seidah, Loss-and gain-of-function PCSK9 variants cleavage specificity, dominant negative effects, and low density lipoprotein receptor (ldlr) degradation, J. Biol. Chem. 287 (2012) 33745-33755.
24. S. Benjannet, D. Rhainds, R. Essalmani, J. Mayne, L. Wickham, W. Jin, M.-C. Asselin, J. Hamelin, M. Varret, D. Allard, M. Trillard, M. Abifadel, A. Tebon, A.D. Attie, D.J. Rader, C. Boileau, L. Brissette, M. Chretien, A. Prat, N.G. Seidah, NARC-1/PCSK9 and its natural mutants, J. Biol. Chem. 279 (47) (2004) 48865-48875.
25. J. Mayne, T.C. Ooi, A. Raymond, M. Cousins, L. Bernier, T. Dewpura, F. Sirois, M. Mbikay, J. Davignon, M. Chretien, Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations, Lipids Health Dis. 12 (2013) 70.
26. J. Caneron, O.L. Holla, T. Rauheim, M.-A. Kulseth, K.E. Berge, T.P. Leren, Effect of mutations in the PCSK9 gene on the cell surface LDL receptors, Hum. Mol. Genet. 15 (9) (2006) 1551-1558.
27. J. Mayne, T. Dewpura, A. Raymond, L. Bernier, M. Cousons, T.C. Ooi, J. Davignon, N.G. Seidah, M. Mbikay, M. Chretien, Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture, Clin. Chem. 57 (10) (2011) 1415-1423.
28. S. Dragan, M.C. Serban, M. Banach, Proprotein convertase Subtilisin/Kexin 9 inhibitors: an emerging lipid-lowering therapy? J. Cardiovasc. Pharmacol. Ther. (2014) pii: 1074248414539562 (Epub ahead of print).
29. P. Stawowy, I.A. Just, E. Kaschina, Inhibition of PCSK9: a novel approach for the treatment of dyslipidemia, Coron. Artery Dis. 25 (4) (2014) 353-359.
30. M. Briel, A.J. Nordmann, H.C. Bucher, Statin therapy for prevention and treatment of acute and chronic cardiovascular disease: update on recent trials and metaanalyses, Curr. Opin. Lipidol. 16 (2005) 601-605.
31. Q. Zhou, J.K. Liao, Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy, Curr. Pharm. Des. 15 (5) (2009) 467-478.
32. O.J. Liakopoulos, Y.H. Choi, E.W. Kuhn, T. Wittwer, M. Borys, N. Madershahian, G. Wassmer, T. Wahlers, Statins for prevention of atrial fibrillation after cardiac surgery: a systematic literature review, J. Thorac. Cardiovasc. Surg. 138 (3) (2008) 678-686.
33. A. Ludman, V. Venugopal, D.M. Yellon, D.J. Hausenloy, Statins and cardioprotectionemore than just lipid lowering, Pharmacol. Ther. 122 (1) (2009) 30-43.
34. C.A. Dujovne, M. Ettinger, J.F. McNeer, L.J. Lipka, A.P. LeBeaut, R. Suresh, B. Yang, Ezetimibe Study Group, Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia, Am. J. Cardiol. 90 (2002) 1092-1097.
35. B.A. Golomb, M.A. Evans, Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism, Am. J. Cardiovasc. Drugs 8 (6) (2008) 373-418.
36. M.A. Silva, A.C. Swanson, P.J. Gandhi, G.R. Tataronis, Statin-related adverse events: a meta-analysis, Clin. Ther. 28 (1) (2006) 26-35.
37. B. Sadowitz, K.G. Maier, V. Gahtan, Basic science review: statin therapyepart I: the pleiotropic effects of statins in cardiovascular disease, Vasc. Endovasc. Surg. 44 (4) (2010) 241-251.
38. T. Eisenberg, M.T. Wells, Statins and risk of incident diabetes, Lancet 375 (9732) (2010) 2140-2142.
39. X.L. Zhang, M. Liu, J. Qian, J.H. Zheng, X.P. Zhang, C.C. Guo, J. Geng, B. Peng, J.P. Che, Y. Wu, Statin use and risk of kidney cancer: a meta-analysis of observational studies and randomized trials, Br. J. Clin. Pharmacol. (Jul 23 2013), http://dx.doi.org/10.1111/bcp.12210 (Epub ahead of print).
40. D. Rozman, K. Minostory, Perspectives of the non-statin hypolipidemic agents, Pharmacol. Ther. 127 (1) (2010) 19-40.
41. D. Lopez, Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia, Drug News Perspect. 21 (6) (2008) 323-330.
42. D. Steinberg, J.L. Witztum, Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels, Proc. Natl. Acad. Sci. U. S. A. 106 (24) (2009) 9546-9547.
43. M.J. Graham, K.M. Lemonidis, C.P. Whipple, A. Subramaniam, B.P. Monia, S.T. Crooke, R.M. Crooke, Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice, J. Lipid Res. 48 (4) (2007) 763-767.
44. M. Frank-Kamenetsky, A. Grefhorst, N.N. Anderson, Racie TS and 27 coauthors. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates, Proc. Natl. Acad. Sci. U. S. A. 105 (33) (2008) 11915-11920.
45. J.C. Chan, D.E. Piper, Q. Cao, D. Liu, C. King, et al., A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates, Proc. Natl. Acad. Sci. U. S. A. 106 (24) (2009) 9820-9825.
46. C.J. Duff, M.J. Scott, I.T. Kirby, S.E. Hutchinson, S.L. Martin, N.M. Hooper, Antibody-mediated disruption of the interaction between PCSK9 and the lowdensity lipoprotein receptor, Biochem. J. 419 (3) (2009) 577-584.
47. E.A. Stein, S. Mellis, G.D. Yancopoulos, N. Stahl, D. Logan, W.B. Smith, E. Lisbon, M. Gutierrez, C. Webb, R. Wu, Y. Du, T. Kranz, E. Gasparino, G.D. Swergold, Effect of a monoclonal antibody to PCSK9 on LDL cholesterol, N. Engl. J. Med. 366 (12) (2012) 1108-1118.
48. C.S. Dias, A.J. Shaywitz, S.M. Wasserman, B.P. Smith, B. Gao, D.S. Stolman, C.P. Crispino, K.V. Smirnakis, M.G. Emery, A. Colbert, J.P. Gibbs, M.W. Retter, B.P. Cooke, S.T. Uy, M. Matson, E.A. Stein, Effects of AMG145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins, J. Am. Coll. Cardiol. 60 (19) (2012) 1888-1898.
49. ClinicalTrialsgov. The Evaluation of PF-04950615 (RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-2). http://clinicaltrials.gov/ct2/show/NCT01975389?term=SPIRE-2&rank=1, Published March 4, 2014, (accessed 19.03.14.).
50. Mason I. PharmaTimes on line, Antibody lipid treatments enter final furlong, www.pharmatimes.com/article/13-09 02/Antibody-lipid-treatments-enter-final-furlong.aspx.
51. R.T. Dadu, C.M. Ballantyne, Lipid lowering with PCSK9 inhibitors, Nat. Rev. Cardiol. (2014) 1-13, http://dx.doi.org/10.1038/nrcardio.2014.84.
52. B. Ecker-Schlipf, Hyperlipidemia. New treatment option with Evolocumab, Med. Monatsschr. Pharm. 37 (7) (2014) 271-272.
53. Y.G. Ni, S. Di Marco, J.H. Condra, L.B. Peterson, W. Wang, F. Wang, S. Pandit, H.A. Hammond, R. Rosa, R.T. Cummings, D.D. Wood, X. Liu, M.J. Bottomley, X. Shen, R.M. Cubbon, S.P. Wang, D.G. Johns, C. Volpari, L. Hamuro, J. Chin, L. Huang, J.Z. Zhao, S. Vitelli, P. Haytko, D. Wisniewski, L.J. Mitnaul, C.P. Sparrow, B. Hubbard, A. Carfí, A. Sitlani, A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo, J. Lipid Res. 52 (1) (2011) 78-86.
54. C.I. Schroeder, J.E. Swedberg, J.M. Withka, K.J. Rosengren, M. Akcan, D.J. Clayton, N.L. Daly, O. Cheneval, K.A. Borzilleri, M. Griffor, I. Stock, B. Colless, P. Walsh, P. Sunderland, A. Reyes, R. Dullea, M. Ammirati, S. Liu, K.F. McClure, M. Tu, S.K. Bhattacharya, S. Liras, D.A. Price, D.J. Craik, Design and synthesis of truncated EGF-A peptides that restore LDL-R recycling in the presence of PCSK9 in vitro, Chem. Biol. 21 (2) (2014) 284-294.
55. G. Mayer, S. Poirier, N.G. Seidah, Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels, J. Biol. Chem. 283 (46) (2008) 31791-31801.
56. N.G. Seidah, S. Poirier, M. Denis, R. Parker, B. Miao, C. Mapelli, A. Prat, H. Wassef, J. Davignon, K.A. Hajjar, G. Mayer, Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation, PLoS ONE 7 (2012) e41865.
57. H. Palmer Smith, A. Basak, Regulatory effects of peptides from the pro and catalytic domains of proprotein convertase subtilisin/Kexin 9 (PCSK9) on LDLR, Curr. Med. Chem. 17 (20) (2010) 2168-2182.
58. J. Cameron, T. Ranheim, M.A. Kulseth, T.P. Leren, K.E. Berge, Berberine decreases PCSK9 expression in HepG2 cells, Atherosclerosis 201 (2) (2008) 266-273.
59. M. Mbikay, Therapeutic potential of moringa oleifera leaves in chronic hyperglycemia and dyslipidemia: a review, Front. Pharmacol. 3 (24) (2012) 1-12.
60. Y. Zhang, C. Eigenbrot, L. Zhou, S. Shia, W. Li, C. Quan, J. Tom, P. Moran, P. Di Lello, N.J. Skelton, M. Kong-Beltran, A. Peterson, D. Kirchhofer, Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor, J. Biol. Chem. 289 (2) (2014) 942-955.
61. L. Shan, L. Pang, R. Zhang, N.J. Murgolo, H. Lan, J.A. Hedrick, PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide, Biochem. Biophys. Res. Commun. 375 (2008) 69-73.
62. L. Trapani, M. Segatto, V. Pallottini, New compounds able to control hepatic cholesterol metabolism: is it possible to avoid statin treatment in aged people? World J. Hepatol. 5 (12) (2013) 676-684.
63. D.E. Piper, S. Jackson, Q. Liu, W.G. Romanow, S. Shetterley, S.T. Thibault, B. Shan, N.P. Walker, The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol, Structure 15 (2007) 545-552.
64. E.N. Hampton, M.W. Knuth, J. Li, J.L. Harris, S.A. Lesley, G. Spraggon, The selfinhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain, Proc. Natl. Acad. Sci. U. S. A. 104 (37) (2007) 14604-14609.
65. T. Yamamoto, C. Lu, R.O. Ryan, A two-step binding model of PCSK9 interaction with the low density lipoprotein receptor, J. Biol. Chem. 288 (7) (2011) 5464-5470.
66. N. Ferri, Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases, Scientifica (2012) 1-21. Article ID 927352.
67. M.J. Bottomley, A. Cirillo, L. Orsatti, et al., Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants, J. Biol. Chem. 284 (2009) 1313-1323.
68. P. Mishra, Q. Qing, A. Gruslin, Y. Hidaka, M. Mbikay, A. Basak, In vitro regulatory effects of epidydimal serpin CRES on protease activity of proprotein convertase 4 (PC4), Curr. Mol. Med. 12 (2012) 1050-1067.
69. I.-R. Tomillero, L.M. Tapia, M. Gongora-Benítez, E. Nicolas, J. Tulla-Puche, F. Albericio, Understanding acid lability of cysteine protecting groups, Molecules 18 (2013) 5155-5162.
70. S. Zhang, F. Lin, M.A. Hossain, F. Shabanpoor, J.D. Wade, Group removal quenching of iodine and isolation of peptide by one step ether precipitation, Int J. Peptide Res. Ther. 14 (4) (2008) 301-305.
71. E. Marcucci, N. Bayo-Puxan, J. Tulla-Puche, J. Spengler, F. Albericio, Cysteine-Strityl a key derivative to prepare N-methyl cysteines, J. Comb. Chem. 10 (2008) 69-78.
72. R.H. Angeletti, L. Bibbs, L.F. Bonewald, G.B. Fields, J.S. McMurray, W.T. Moore, J.T. Stults, Formation of a Disulfide Bond in an Octreotide-like Peptide: a Multicenter Study, in: Techniques in Protein Chemistry VII, Academic Press, Inc, 1996.
73. M.C. Liu, S. Yut, J. Sy, Colvin, C.M. Redmant, F. Lipmann, Tyrosine sulfation of proteins from the human hepatoma cell line HepG2, Proc. Natl. Acad. Sci. U. S. A. 82 (1985) 7160-7164.
74. T. Zor, Z. Selinger, Linearization of the Bradford protein assay increases its sensitivity: theoretical and experimental studies, Anal. Biochem. 236 (1996) 302-306.
75. T. Kosenko, M. Golder, G. Leblond, W. Weng, T.A. Lagace, Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation, J. Biol. Chem. 288 (12) (2013) 8279-8288.
76. M.A. Nguyen, T. Kosenko, T.A. Lagace, Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts, J. Lipid Res. 55 (2) (2014) 266-275.
77. A. Basak, A. Mitra, S. Basak, C. Pasko, M. Chretien, P. Seaton, A fluorogenic peptide containing the processing site of human SARS corona virus S-protein kinetic evaluation and NMR structure elucidation, ChemBioChem 8 (2007) 1-10.
78. J. van Meerloo, G.J. Kaspers, J. Cloos, Cell sensitivity assays: the MTT assay, Methods Mol. Biol. 731 (2011) 237-245.
79. A. Basak, F. Lotfipour, Modulating furin activity with designed mini-PDX peptides: synthesis and in vitro kinetic evaluation, FEBS Lett. 579 (2005) 4813-4821.
80. A. Basak, J.C. Shain, U.K. Khamrai, K.R. Rudra, A. Basak, Nitrogen substituted cyclic azaenediynes: synthesis, thermal reactivity and complexation with metal ions, J. Chem. Soc. Perkin Trans. 1 (2000) 1955-1964.
81. M. van de Weert, L. Stella, Fluorescence quenching and ligand binding: a critical discussion of a popular methodology, J. Mol. Struct. 998 (1-3) (2011) 144-150.
82. Matrices Probes Hand book, Avidin, Streptavidin, NeutrAvidin and CaptAvidin Biotin-Binding Proteins and Affinity, Section 7.6.
83. A.M. Münzer, W. Seo, G.J. Morgan, Z.P. Michael, Y. Zhao, K. Melzer, G. Scarpa, A. Star, Sensing reversible protein-ligand interactions with single-walled carbon nanotube field-effect transistors, J. Phys. Chem. C. Nanomater Interfaces 118 (31) (2014) 17193-17199.
84. A. Naimushin, M. Lidar, I. Ben Zvi, A. Livneh, The structural effect of the E148Q MEFV mutation on the pyrin protein: a study using a quantum chemistry model, Isr. Med. Assoc. J. 13 (4) (2011) 199-201.
85. L.E. Hollister, W.L. Arons, Effect of dextro-isomers of thyroid hormones on serum cholesterol levels in euthyroid hypercholesterolemic patients, Ann. Int. Med. 56 (1962) 570-576.
86. L. Gentilucci, R. De Marco, L. Cerisoli, Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudopeptide bonds, and cyclization, Curr. Pharm. Des. 16 (28) (2010) 3185-3203.
87. Y. Hamada, Y. Kiso, The application of bioisosteres in drug design for novel drug discovery: focusing on acid protease inhibitors, Expert Opin. Drug Discov. 7 (10) (2012) 903-922.
88. C. Shivamallu, U. Sharanaiah, S.P. Kollur, N.K. Mallesh, R.D. Hosakere, V. Balamurugan, Pseudo-peptides as novel antileptospiral agents: synthesis and spectral characterization, Spectrochim. Acta A Mol. Biomol. Spectrosc. 118 (2014) 1152-1157.
89. M. Weinreich, W.H. Frishman, Antihyperlipidemic therapies targeting PCSK9, Cardiol. Rev. (2014) 140-146.
90. G.D. Norata, Established and emerging approaches for the management of dyslipidaemia, Scientifica (2012) 14. Article ID 482423.
91. Y.J. Jia, R.X. Xu, J. Sun, Y. Tang, J.J. Li, Enhanced circulating PCSK9 concentration by berberine through SREBP-2 pathway in high fat diet-fed rats, J. Transl. Med. 12 (103) (2014) 1-8.
92. S. Wadhwa, M.S. Panwar, N. Saini, S. Rawat, S. Singha, A review on commercial, traditional uses, phytoconstituents and pharmacological activity of Moringa Oleifera, Glob. J. Trad. Med. Sys. 2 (1) (2013) 1-13.